Clinical trials: Depressive Disorder NOS
Bipolar Disorder, Schizophrenia
Life Goals Collaborative Care to Improve Health Outcomes in Mental Disorders
Persons with serious mental illness (SMI) are at increased risk of cardiovascular disease (CVD). The goals of this study are to test a treatment, Life Goals Collaborative Care to help promote health behavior change and improve…
- Conditions
- Bipolar Disorder, Schizophrenia, Major Depressive Disorder, Schizoaffective Disorder
- Trial name
- NCT01487668
- Testing
- Life Goals Collaborative Care
- Where
- United States
- Volunteers
- 304 people
- Sponsor
- VA Office of Research and Development
Depressive Disorder, Treatment-Resistant
Treatment Resistant Depression (Pilot)
Treatment resistant depression (TRD) is a major public health problem. Current therapeutic options for this patient population remain limited.
- Trial name
- NCT01179009
- Testing
- Ketamine, Clonidine
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Washington University School of Medicine
Major Depressive Disorder
A Study to Assess the Efficacy and Safety of REL-1017 as Adjunctive Treatment for Major Depressive Disorder (MDD)
This is an outpatient, 2-arm, Phase 3, multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of REL-1017 once daily (QD) as an adjunctive treatment of Major Depressive Disorder.
- Trial name
- Reliance I (NCT04688164)
- Testing
- REL-1017
- Where
- 11 sites in United States
- Volunteers
- 227 people
- Sponsor
- Relmada Therapeutics, Inc.
Major Depressive Disorder
A Clinical Study to Evaluate of Single and Multiple Oral Doses of GM-1020 in Patients With MDD
The aim of this Phase 2a study in patients with MDD is to assess safety and tolerability and preliminary antidepressant efficacy.
- Trial name
- NCT06309277
- Testing
- GM-1020
- Where
- United Kingdom
- Volunteers
- 46 people
- Sponsor
- Gilgamesh Pharmaceuticals
Major Depressive Disorder
5-hydroxytryptophan and Creatine for Treatment Resistant Depression Associated With Hypoxia in Females
The investigators hypothesize that the administration of two widely available, naturally occurring dietary supplements, 5 hydroxytryptophan and creatine monohydrate, will reduce the severity of depression in individuals exposed…
- Trial name
- NCT02356107
- Testing
- 5-hydroxytryptophan and Creatine monohydrate
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Perry Renshaw
Major Depressive Disorder, Bipolar Disorder
The Role of Dopamine Metabolism in the Antidepressant Effects of Sleep Deprivation and Sertraline in Depressed Patients
This study evaluates the efficacy of sleep deprivation treatment in accelerating antidepressant responses when administered during the first week of medications and augmenting a sustained response with chronobiological…
- Trial name
- NCT00581009
- Testing
- chronobiological augmentation, sertraline, lithium, one night of sleep deprivation and two FDG PET scans
- Where
- 2 sites in United States
- Volunteers
- 49 people, healthy volunteers welcome
- Sponsor
- University of California, Irvine
Major Depressive Disorder
Goal Achievement After a Change to Vortioxetine in Adults With Major Depressive Disorder
The purpose of this study is to determine the effectiveness of treatment with vortioxetine on participant goal achievement after a change in antidepressant medication for the treatment of major depressive disorder (MDD).
- Trial name
- NCT02972632
- Testing
- Vortioxetine
- Where
- 25 sites in United States
- Volunteers
- 123 people
- Sponsor
- Takeda
Major Depressive Disorder
Evaluation of a Mental Health Physician Support Program in Nova Scotia
The aim of this study is to test the program's effectiveness in a primary care setting in reducing stigma among medical personnel, increasing the comfort level of physicians and staff in providing care to those living with mental…
- Trial name
- NCT01975948
- Testing
- Mental Health Practice Support Program, Treatment as Usual
- Where
- Canada
- Volunteers
- 285 people
- Sponsor
- Nova Scotia Health Authority
Major Depressive Disorder
PET Biomarkers in Treatment Resistant Depression
The primary objectives of the study are to test whether brain Mono Amine Oxidase-A (MAO-A) levels are elevated in patients with treatment-resistant major depression, and to explore whether MAO-A brain levels predict treatment…
- Trial name
- NCT01031810
- Testing
- tranylcypromine
- Where
- United States
- Volunteers
- 13 people, healthy volunteers welcome
- Sponsor
- New York State Psychiatric Institute
Treatment Resistant Depression
A Study in Relapse Prevention of Treatment-Resistant Depression
The purpose of this study is to determine whether olanzapine and fluoxetine combination (OFC) if used for a long time (47 weeks) makes patients suffering from Treatment Resistant Depression stable, determine if OFC is safe when…
- Trial name
- NCT00958568
- Testing
- Olanzapine and Fluoxetine combination (OFC), Fluoxetine
- Where
- 66 sites in United States, Argentina and 6 more
- Volunteers
- 892 people
- Sponsor
- Eli Lilly and Company
Major Depressive Disorder
A Trial to Evaluate the Efficacy, Safety & Tolerability of Brexpiprazole in the Maintenance Treatment of Adults With Major Depressive Disorder
Major depressive disorder (MDD) is a serious medical illness associated with significant suicidal risk and marked disability. Despite the availability of numerous treatments, achievement of consistent and favorable long-term…
- Trial name
- NCT03538691
- Testing
- Brexpiprazole, Antidepressant therapy
- Where
- United States
- Volunteers
- 1,149 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Major Depression
Antidepressant Effects of NR2B in Major Depression
Purpose : This study will determine whether MK-0657, a selective NR2B Antagonist, can quickly improve symptoms of depressed mood, psychomotor retardation, poor motivation and reduced enjoyment of things in patients with major…
- Trial name
- NCT00472576
- Testing
- MK-0657
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- National Institute of Mental Health (NIMH)
Major Depressive Disorder
CBT+ for Depression
This study investigates the effects of a novel intervention approach, intentionally sequencing aerobic exercise immediately prior to therapy sessions (i.e., cognitive behavioral therapy [CBT]) to determine its effects on both…
- Trial name
- CBT+ (NCT06001346)
- Testing
- ActiveCBT, CalmCBT
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- University of Wisconsin, Madison
Autism Spectrum Disorder, Depression
TMS for Adults With Autism and Depression
The goal of this proposal is to investigate whether a standard rTMS protocol for depression, including multiple sessions applied to left dorsolateral prefrontal cortex (DLPFC) results in reduction of depressive symptoms for adult…
- Conditions
- Autism Spectrum Disorder, Depression, Depressive Disorder, Major Depressive Disorder
- Trial name
- TAD (NCT02939560)
- Testing
- NeuroStar® TMS device (Neuronetics, Atlanta, GA)
- Where
- United States
- Volunteers
- 13 people, healthy volunteers welcome
- Sponsor
- Medical University of South Carolina
Major Depressive Disorder
The Safety and Efficacy of Escitalopram in Pediatric Patients With Major Depressive Disorder
Depression affects approximately 2.5% of children and 8% of adolescents. Escitalopram is the S-enantiomer of citalopram. Both escitalopram and citalopram are selective serotonin reuptake inhibitors (SSRIs) and are used to treat…
- Trial name
- NCT00107120
- Testing
- Escitalopram
- Where
- 28 sites in United States
- Volunteers
- 312 people
- Sponsor
- Forest Laboratories
Dysthymic Disorder, Depressive Disorder NOS
Duloxetine for Chronic Depression: a Double-blind Study
The investigators are studying a new antidepressant medicine, duloxetine, for the treatment of people with chronic depression. Duloxetine (trade name Cymbalta) was recently approved by the FDA for the treatment of major…
- Trial name
- NCT00360724
- Testing
- Duloxetine (Cymbalta)
- Where
- United States
- Volunteers
- 65 people
- Sponsor
- New York State Psychiatric Institute
Depressive Disorder, Treatment-Resistant
A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression
The purpose of this study is to assess the safety and tolerability of esketamine nasal spray in participants with treatment-resistant depression (TRD).
- Trial name
- SUSTAIN-3 (NCT02782104)
- Testing
- Esketamine Nasal Spray
- Where
- 173 sites in United States, Argentina and 24 more
- Volunteers
- 1,148 people
- Sponsor
- Janssen Research & Development, LLC
Alcohol Abuse, Schizophrenia
Contingency Management of Alcohol Abuse in the Severely Mentally ILL
The investigators will evaluate the efficacy of a comprehensive 12-week contingency management intervention for treating alcohol dependence for persons with severe mental illness who are seen within the context of a community…
- Conditions
- Alcohol Abuse, Schizophrenia, Bipolar Disorder, Major Depressive Disorder
- Trial name
- CMETG (NCT01567943)
- Testing
- Contingency Management
- Where
- United States
- Volunteers
- 123 people
- Sponsor
- University of Washington
Major Depressive Disorder
Depressed Mood Improvement Through Nicotine Dosing (Depressed MIND Study)
Late-life depression is characterized by both affective (mood) symptoms and cognitive deficits. There is currently no intervention that may provide consistent benefits to both mood and cognitive performance.
- Trial name
- NCT02816138
- Testing
- Nicotine
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Vanderbilt University Medical Center
Treatment Resistant Depression, Generalized Anxiety Disorder
An Open Label Study of Clinical Utility and Patient Outcomes of the Genecept Assay
Genomind has developed and introduced a battery of genetic tests, the Genecept Assay, which clinicians can administer to patients using a simple saliva sample technique. The present study proposes to enroll 1.
- Trial name
- COM-1 (NCT01507155)
- Testing
- Genecept Assay
- Where
- United States
- Volunteers
- 685 people
- Sponsor
- Genomind, LLC